Blend: Ipamorelin CJC-1295 (No DAC) 20MG
0What is the CJC-1295 + Ipamorelin Peptide Combination?
The combination of CJC-1295 No DAC (Modified GRF 1-29) and Ipamorelin represents a strategic pairing of two distinct growth hormone secretagogues that operate through complementary mechanisms. CJC-1295 No DAC is a GHRH (growth hormone-releasing hormone) analog with enhanced α-helical structure and 49-fold greater potency than native GHRH in rat pituitary cells, activating the GHRH receptor pathway. Ipamorelin is a selective GHRP (growth hormone-releasing peptide) that activates the ghrelin recep
Frequently Asked Questions
What is the CJC-1295 + Ipamorelin Peptide Combination?
The combination of CJC-1295 No DAC (Modified GRF 1-29) and Ipamorelin represents a strategic pairing of two distinct growth hormone secretagogues that operate through complementary mechanisms. CJC-1295 No DAC is a GHRH (growth hormone-releasing hormone) analog with enhanced α-helical structure and 49-fold greater potency than native GHRH in rat pituitary cells, activating the GHRH receptor pathway. Ipamorelin is a selective GHRP (growth hormone-releasing peptide) that activates the ghrelin recep
What makes this combination selective for GH release?
Both components preserve hormonal selectivity. CJC-1295 No DAC, as a GHRH analog, naturally targets somatotrophs specifically. Ipamorelin is unique among GHRPs in producing no significant ACTH or cortisol elevation even at doses 200-fold above its GH ED₅₀—effects statistically indistinguishable from GHRH itself. This contrasts with GHRP-6 and GHRP-2, which elevated ACTH to 300-350% of GHRH levels. Neither compound affects FSH, LH, PRL, or TSH, providing genuine selectivity for the GH axis.
What is the optimal timing for administering both compounds together?
Preclinical studies indicate that simultaneous or near-simultaneous administration produces maximal synergy, with synergistic effects declining as the interval between administrations exceeds 15-30 minutes. Both compounds have matched temporal profiles: CJC-1295 No DAC and Ipamorelin produce peak effects within 15-30 minutes and return to baseline within 2-3 hours based on GHRH and GHRP pharmacology. This matched timing enables coordinated dual-pathway activation. However, these parameters deriv
What does "No DAC" mean in CJC-1295 No DAC?
"No DAC" indicates this version lacks the Drug Affinity Complex component that extends half-life in CJC-1295 with DAC. Modified GRF(1-29) without DAC has shorter duration of action (2-3 hours based on GHRH analog pharmacology) compared to the extended-release formulation. This shorter duration is actually advantageous for combination protocols, as it allows multiple daily administrations that can recreate pulsatile GH patterns more closely approximating physiological secretion when paired with t